GPC1 and Familial prostate cancer: This hypothesis is fully supported by a report of Quach et al. (2019) where the inhibition of the glypican-1 (GPC-1) prostate cancer biomarker in the aggressive prostate cancer cell line PC-3 decreased cell growth and migration in vitro, but increased PC-3 tumor size in NCr nude mice xenografts.